跳转至内容
Merck
CN

A preclinical xenograft model of prostate cancer using human tumors.

Nature protocols (2013-04-06)
Mitchell G Lawrence, Renea A Taylor, Roxanne Toivanen, John Pedersen, Sam Norden, David W Pook, Mark Frydenberg, Melissa M Papargiris, Birunthi Niranjan, Michelle G Richards, Hong Wang, Anne T Collins, Norman J Maitland, Gail P Risbridger
摘要

Most cases of prostate cancer are now diagnosed as moderate-grade localized disease. These tumor specimens are important tools in the discovery and translation of prostate cancer research; however, unlike more advanced tumors, they are notoriously difficult to grow in the laboratory. We developed a system for efficiently xenografting localized human prostate cancer tissue, and we adapted this protocol to study the interactions between the specific subsets of epithelial and stromal cells. Fresh prostate tissues or isolated epithelial cells are recombined with mouse seminal vesicle mesenchyme (SVM) and grafted under the renal capsule of immunodeficient mice for optimum growth and survival. Alternatively, mouse mesenchyme can be replaced with human prostate fibroblasts in order to determine their contribution to tumor progression. Grafts can be grown for several months to determine the effectiveness of novel therapeutic compounds when administered to host mice, thereby paving the way for personalizing the treatment of individual prostate cancers.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
胶原酶 来源于溶组织梭菌, for general use, Type I, ≥125 CDU/mg solid
Sigma-Aldrich
透明质酸酶 来源于绵羊睾丸, Type II, lyophilized powder, ≥300 units/mg solid
Sigma-Aldrich
抗-雄激素受体 兔抗, affinity isolated antibody, buffered aqueous solution